Scientific poster: Advantage of antibody based selectivity in the purification of biologics
Posted: 26 June 2019 | Thermo Fisher Scientific | No comments yet
ADVANCES in biotherapeutics are generating an increasing range of complex molecules that present unique and often complex purification challenges.
By taking advantage of antibody based selectivity, Camelid heavy-chain antibody fragments (VHHs) have proven to be a reliable immunoaffinity chromatography (IAC) solution in the downstream process of biologics. ThermoScientific™ CaptureSelect™ affinity products and analytical tools are developed for the discovery and manufacturing of even the most demanding biotherapeutics.
Related content from this organisation
- Whitepaper: Drug repurposing trends and strategic approaches for shortening timelines
- Implementing the FAIR data principles is now a critical endeavour
- The role of digital transformation in achieving Pharma 4.0
- How COVID-19 has accelerated digital transformation and how laboratory orchestration platforms are changing the landscape
- Enabling compliant data management with a comprehensive informatics solution
Related topics
Analytical techniques, Antibodies, Biologics, Bioproduction, Drug Discovery, Drug Manufacturing
